PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background & Aims:Aim of this study was to evaluate whether the PNPLA3 I148M polymorphism, previously associated with hepatocellular carcinoma (HCC) risk, influences the clinical presentation of HCC and survival.Methods:we considered 460 consecutive HCC patients referred to tertiary care centers in Northern Italy, 353 with follow-up data.Results:Homozygosity for PNPLA3 148M at risk allele was enriched in HCC patients with alcoholic liver disease or nonalcoholic fatty liver disease (ALD&NAFLD: relative risk 5.9, 95% c.i. 3.5-9.9; other liver diseases: relative risk 1.9, 95% c.i. 1.1-3.4). In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p

Original languageEnglish
Article numbere75982
JournalPLoS One
Volume8
Issue number10
DOIs
Publication statusPublished - Oct 14 2013

Fingerprint

hepatoma
Polymorphism
Hepatocellular Carcinoma
genetic polymorphism
Liver
Survival
liver diseases
relative risk
Fibrosis
Alleles
alleles
Alcoholic Liver Diseases
fatty liver
alcohol abuse
homozygosity
Tertiary Care Centers
Italy
Liver Diseases
Non-alcoholic Fatty Liver Disease

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{8df510bad4d14241a1f4659bb3c962f3,
title = "PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma",
abstract = "Background & Aims:Aim of this study was to evaluate whether the PNPLA3 I148M polymorphism, previously associated with hepatocellular carcinoma (HCC) risk, influences the clinical presentation of HCC and survival.Methods:we considered 460 consecutive HCC patients referred to tertiary care centers in Northern Italy, 353 with follow-up data.Results:Homozygosity for PNPLA3 148M at risk allele was enriched in HCC patients with alcoholic liver disease or nonalcoholic fatty liver disease (ALD&NAFLD: relative risk 5.9, 95{\%} c.i. 3.5-9.9; other liver diseases: relative risk 1.9, 95{\%} c.i. 1.1-3.4). In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p",
author = "Luca Valenti and Motta, {Benedetta Maria} and Giorgio Soardo and Massimo Iavarone and Benedetta Donati and Angelo Sangiovanni and Alessia Carnelutti and Paola Dongiovanni and Raffaela Rametta and Cristina Bertelli and Floriana Facchetti and Massimo Colombo and Silvia Fargion and Fracanzani, {Anna Ludovica}",
year = "2013",
month = "10",
day = "14",
doi = "10.1371/journal.pone.0075982",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma

AU - Valenti, Luca

AU - Motta, Benedetta Maria

AU - Soardo, Giorgio

AU - Iavarone, Massimo

AU - Donati, Benedetta

AU - Sangiovanni, Angelo

AU - Carnelutti, Alessia

AU - Dongiovanni, Paola

AU - Rametta, Raffaela

AU - Bertelli, Cristina

AU - Facchetti, Floriana

AU - Colombo, Massimo

AU - Fargion, Silvia

AU - Fracanzani, Anna Ludovica

PY - 2013/10/14

Y1 - 2013/10/14

N2 - Background & Aims:Aim of this study was to evaluate whether the PNPLA3 I148M polymorphism, previously associated with hepatocellular carcinoma (HCC) risk, influences the clinical presentation of HCC and survival.Methods:we considered 460 consecutive HCC patients referred to tertiary care centers in Northern Italy, 353 with follow-up data.Results:Homozygosity for PNPLA3 148M at risk allele was enriched in HCC patients with alcoholic liver disease or nonalcoholic fatty liver disease (ALD&NAFLD: relative risk 5.9, 95% c.i. 3.5-9.9; other liver diseases: relative risk 1.9, 95% c.i. 1.1-3.4). In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p

AB - Background & Aims:Aim of this study was to evaluate whether the PNPLA3 I148M polymorphism, previously associated with hepatocellular carcinoma (HCC) risk, influences the clinical presentation of HCC and survival.Methods:we considered 460 consecutive HCC patients referred to tertiary care centers in Northern Italy, 353 with follow-up data.Results:Homozygosity for PNPLA3 148M at risk allele was enriched in HCC patients with alcoholic liver disease or nonalcoholic fatty liver disease (ALD&NAFLD: relative risk 5.9, 95% c.i. 3.5-9.9; other liver diseases: relative risk 1.9, 95% c.i. 1.1-3.4). In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p

UR - http://www.scopus.com/inward/record.url?scp=84885402417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885402417&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0075982

DO - 10.1371/journal.pone.0075982

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e75982

ER -